Share on StockTwits

RTI Biologics Inc. (NASDAQ:RTIX) updated its FY14 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.06-0.08 for the period, compared to the Thomson Reuters consensus estimate of $0.06, American Banking and Market News reports. The company issued revenue guidance of $245-250 million, compared to the consensus revenue estimate of $246.92 million.RTI Biologics also updated its Q1 guidance to $0.00 EPS.

On a related note, analysts at Zacks upgraded shares of RTI Biologics from an underperform rating to a neutral rating in a research note on Tuesday, December 31st. They now have a $3.50 price target on the stock.

Shares of RTI Biologics Inc. (NASDAQ:RTIX) traded up 9.66% during mid-day trading on Thursday, hitting $3.575. 163,620 shares of the company’s stock traded hands. RTI Biologics Inc. has a 1-year low of $2.77 and a 1-year high of $4.53. The stock has a 50-day moving average of $3.28 and a 200-day moving average of $3.37. The company’s market cap is $201.1 million.

RTI Biologics (NASDAQ:RTIX) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.01). The company had revenue of $60.50 million for the quarter, compared to the consensus estimate of $59.20 million. During the same quarter in the prior year, the company posted $0.04 earnings per share. The company’s quarterly revenue was up 35.7% on a year-over-year basis.

RTI Biologics, Inc process human musculoskeletal and other tissue. It also processes bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE and TUTOPLAST sterilization processes, for distribution to hospitals and surgeons.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.